Vaccine composition comprising an antigen and a peptide having adjuvant properties

US8900564B2 · kind B2 · utility

Assignee

• Valneva Austria GmbH · AT

Inventors

• Jörg Fritz · Wien, AT
• Frank Mattner · Wien, AT
• Wolfgang Zauner · Wien, AT
• Eszter Nagy · Wien, AT
• Michael Buschle · Perchtoldsdorf, AT

Key dates

• Filing date: May 21, 2008
• Grant date: Dec 2, 2014
• Expiry date: Jul 13, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independently one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.